Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-06-02

AUTHORS

Yoshishige Samukawa, Hirohisa Omiya, Hirotaka Watase, Kazunari Nozaki, Soichi Sakai, Rimei Nishimura

ABSTRACT

IntroductionIn our previous study investigating effects of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, on 24-h glycemic variability by continuous glucose monitoring (CGM), luseogliflozin elicited parallel downward shifts in fasting and postprandial glucose levels. However, further review of individual patients’ data revealed that postprandial hyperglycemia was not reduced in some patients, while preprandial glucose was ameliorated in most patients. Therefore, we divided patients into two groups according to their postprandial glucose responses and conducted a post hoc subanalyses to elucidate which factors contributed to the differential effects of luseogliflozin.MethodsThirty-four Japanese type 2 diabetic patients in our previous randomized, double-blind, placebo-controlled, crossover study with 7-day luseogliflozin administration were divided into postprandial glucose responders (PGR, n = 23, ameliorated peak glucose) and postprandial glucose non-responders (PGNR; n = 11, non-ameliorated peak glucose). Baseline characteristics, variations in CGM-measured 24-h glucose levels, and other pharmacodynamic variabilities were compared.ResultsBaseline characteristics did not differ significantly between groups. Placebo-subtracted peak glucose was significantly lowered in PGR and significantly increased in PGNR (−43.8 and 17.9 mg/dL; both p < 0.05). Luseogliflozin significantly lowered “lowest glucose” (defined as the lowest level measured throughout a 24-h period) similarly in PGR and PGNR (−19.2 and −24.0 mg/dL; both p < 0.05), significantly reduced the mean amplitude of glucose excursions in PGR (−15.50 mg/dL; p < 0.05), and increased the area under the curve for plasma glucagon over 24 h in PGNR (median difference vs. placebo: 240 pg/mL h; p < 0.05). Luseogliflozin increased urinary glucose excretion (UGE) and decreased serum insulin by similar magnitudes in both groups.ConclusionsLuseogliflozin diminished glucose fluctuations in most patients by lowering peak glucose to a greater extent than lowest glucose. Luseogliflozin may also lower lowest glucose in patients whose peak glucose was not ameliorated despite increasing UGE. The glucagon increase in PGNR might explain its hypoglycemic effect on postprandial glucose.FundingTaisho Pharmaceutical Co., Ltd, Tokyo, Japan.Trial RegistrationJapicCTI-142548. More... »

PAGES

1215-1230

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12325-016-0350-5

DOI

http://dx.doi.org/10.1007/s12325-016-0350-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1003457836

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/27255763


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Blood Glucose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cross-Over Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hyperglycemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypoglycemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postprandial Period", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sorbitol", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Samukawa", 
        "givenName": "Yoshishige", 
        "id": "sg:person.01044115456.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044115456.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Omiya", 
        "givenName": "Hirohisa", 
        "id": "sg:person.01034253641.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034253641.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watase", 
        "givenName": "Hirotaka", 
        "id": "sg:person.01362135451.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362135451.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nozaki", 
        "givenName": "Kazunari", 
        "id": "sg:person.01314022251.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314022251.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.419836.1", 
          "name": [
            "Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sakai", 
        "givenName": "Soichi", 
        "id": "sg:person.01133661156.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133661156.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-19-18 Nishi-shimbashi, Minato-ku, 105-0003, Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.411898.d", 
          "name": [
            "Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-19-18 Nishi-shimbashi, Minato-ku, 105-0003, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nishimura", 
        "givenName": "Rimei", 
        "id": "sg:person.0745514477.90", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745514477.90"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s12325-015-0200-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027959488", 
          "https://doi.org/10.1007/s12325-015-0200-x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12933-014-0169-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040395366", 
          "https://doi.org/10.1186/s12933-014-0169-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40265-014-0230-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007759159", 
          "https://doi.org/10.1007/s40265-014-0230-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrendo.2011.243", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038216268", 
          "https://doi.org/10.1038/nrendo.2011.243"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13300-013-0042-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005579084", 
          "https://doi.org/10.1007/s13300-013-0042-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12272-014-0419-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048225579", 
          "https://doi.org/10.1007/s12272-014-0419-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.3828", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033956920", 
          "https://doi.org/10.1038/nm.3828"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-06-02", 
    "datePublishedReg": "2016-06-02", 
    "description": "IntroductionIn our previous study investigating effects of luseogliflozin, a sodium\u2013glucose cotransporter 2 inhibitor, on 24-h glycemic variability by continuous glucose monitoring (CGM), luseogliflozin elicited parallel downward shifts in fasting and postprandial glucose levels. However, further review of individual patients\u2019 data revealed that postprandial hyperglycemia was not reduced in some patients, while preprandial glucose was ameliorated in most patients. Therefore, we divided patients into two groups according to their postprandial glucose responses and conducted a post hoc subanalyses to elucidate which factors contributed to the differential effects of luseogliflozin.MethodsThirty-four Japanese type 2 diabetic patients in our previous randomized, double-blind, placebo-controlled, crossover study with 7-day luseogliflozin administration were divided into postprandial glucose responders (PGR, n\u00a0=\u00a023, ameliorated peak glucose) and postprandial glucose non-responders (PGNR; n\u00a0=\u00a011, non-ameliorated peak glucose). Baseline characteristics, variations in CGM-measured 24-h glucose levels, and other pharmacodynamic variabilities were compared.ResultsBaseline characteristics did not differ significantly between groups. Placebo-subtracted peak glucose was significantly lowered in PGR and significantly increased in PGNR (\u221243.8 and 17.9\u00a0mg/dL; both p\u00a0<\u00a00.05). Luseogliflozin significantly lowered \u201clowest glucose\u201d (defined as the lowest level measured throughout a 24-h period) similarly in PGR and PGNR (\u221219.2 and \u221224.0\u00a0mg/dL; both p\u00a0<\u00a00.05), significantly reduced the mean amplitude of glucose excursions in PGR (\u221215.50\u00a0mg/dL; p\u00a0<\u00a00.05), and increased the area under the curve for plasma glucagon over 24\u00a0h in PGNR (median difference vs. placebo: 240\u00a0pg/mL\u00a0h; p\u00a0<\u00a00.05). Luseogliflozin increased urinary glucose excretion (UGE) and decreased serum insulin by similar magnitudes in both groups.ConclusionsLuseogliflozin diminished glucose fluctuations in most patients by lowering peak glucose to a greater extent than lowest glucose. Luseogliflozin may also lower lowest glucose in patients whose peak glucose was not ameliorated despite increasing UGE. The glucagon increase in PGNR might explain its hypoglycemic effect on postprandial glucose.FundingTaisho Pharmaceutical Co., Ltd, Tokyo, Japan.Trial RegistrationJapicCTI-142548.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12325-016-0350-5", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1096634", 
        "issn": [
          "0741-238X", 
          "1865-8652"
        ], 
        "name": "Advances in Therapy", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "7", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "33"
      }
    ], 
    "keywords": [
      "urinary glucose excretion", 
      "continuous glucose monitoring", 
      "peak glucose", 
      "most patients", 
      "postprandial glucose", 
      "postprandial hyperglycemia", 
      "low glucose", 
      "glucose levels", 
      "Japanese type 2 diabetic patients", 
      "sodium-glucose cotransporter 2 inhibitors", 
      "type 2 diabetic patients", 
      "effect of luseogliflozin", 
      "cotransporter 2 inhibitors", 
      "postprandial glucose levels", 
      "postprandial glucose response", 
      "parallel downward shift", 
      "luseogliflozin administration", 
      "ResultsBaseline characteristics", 
      "baseline characteristics", 
      "glucose excretion", 
      "diabetic patients", 
      "serum insulin", 
      "crossover study", 
      "plasma glucagon", 
      "glucagon increase", 
      "preprandial glucose", 
      "pharmacodynamic variability", 
      "glycemic variability", 
      "glucose excursions", 
      "Controlled Study", 
      "individual patients", 
      "luseogliflozin", 
      "glucose fluctuations", 
      "hypoglycemic effect", 
      "patients", 
      "glucose response", 
      "glucose monitoring", 
      "further review", 
      "hyperglycemia", 
      "mean amplitude", 
      "subanalyses", 
      "Analyzing Responses", 
      "differential effects", 
      "PgR", 
      "glucose", 
      "group", 
      "previous studies", 
      "similar magnitude", 
      "glucagon", 
      "responders", 
      "excretion", 
      "insulin", 
      "administration", 
      "response", 
      "study", 
      "greater extent", 
      "levels", 
      "effect", 
      "inhibitors", 
      "review", 
      "substantial effect", 
      "factors", 
      "downward shift", 
      "increase", 
      "variability", 
      "excursion", 
      "monitoring", 
      "characteristics", 
      "extent", 
      "data", 
      "curves", 
      "Japan", 
      "area", 
      "amplitude", 
      "Ltd", 
      "Tokyo", 
      "magnitude", 
      "variation", 
      "shift", 
      "fluctuations", 
      "Co."
    ], 
    "name": "Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study", 
    "pagination": "1215-1230", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1003457836"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12325-016-0350-5"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "27255763"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12325-016-0350-5", 
      "https://app.dimensions.ai/details/publication/pub.1003457836"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:41", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_691.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12325-016-0350-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-016-0350-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-016-0350-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-016-0350-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-016-0350-5'


 

This table displays all metadata directly associated to this object as RDF triples.

264 TRIPLES      21 PREDICATES      127 URIs      112 LITERALS      21 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12325-016-0350-5 schema:about N3f73886f43f14703ad24fd862701e078
2 N3fc498d775df4e739ccb5a0ed115afc4
3 N49411d0a4ecd4270989ef2cb0eae1739
4 N50cab4b59fe242deb040c996a2b5a6c8
5 N665f589670b0489c9e2d395844f54299
6 N675e3d09d908497ebf1cf63dc797fd41
7 N700f8149353a4c288b6bf4b124b3c700
8 N71b3113eae1e49b9b6e0a41c354b2eb2
9 N7679a15c114948f6a4b3d554fe302440
10 Nb2143e78fe814540a5f29e735b65a988
11 Nb835c7e2b1374aeeb1387b6bd6a1bfc5
12 Ne0466cc0229849099ec9b11e1aa49d68
13 Ne85683e735014b0b91d823e181334cc3
14 Neec0b93a95a245b189be66ce2f058fee
15 anzsrc-for:11
16 anzsrc-for:1103
17 schema:author N22d95ff84ede41f6b5e5520a67da6650
18 schema:citation sg:pub.10.1007/s12272-014-0419-0
19 sg:pub.10.1007/s12325-015-0200-x
20 sg:pub.10.1007/s13300-013-0042-y
21 sg:pub.10.1007/s40265-014-0230-8
22 sg:pub.10.1038/nm.3828
23 sg:pub.10.1038/nrendo.2011.243
24 sg:pub.10.1186/s12933-014-0169-9
25 schema:datePublished 2016-06-02
26 schema:datePublishedReg 2016-06-02
27 schema:description IntroductionIn our previous study investigating effects of luseogliflozin, a sodium–glucose cotransporter 2 inhibitor, on 24-h glycemic variability by continuous glucose monitoring (CGM), luseogliflozin elicited parallel downward shifts in fasting and postprandial glucose levels. However, further review of individual patients’ data revealed that postprandial hyperglycemia was not reduced in some patients, while preprandial glucose was ameliorated in most patients. Therefore, we divided patients into two groups according to their postprandial glucose responses and conducted a post hoc subanalyses to elucidate which factors contributed to the differential effects of luseogliflozin.MethodsThirty-four Japanese type 2 diabetic patients in our previous randomized, double-blind, placebo-controlled, crossover study with 7-day luseogliflozin administration were divided into postprandial glucose responders (PGR, n = 23, ameliorated peak glucose) and postprandial glucose non-responders (PGNR; n = 11, non-ameliorated peak glucose). Baseline characteristics, variations in CGM-measured 24-h glucose levels, and other pharmacodynamic variabilities were compared.ResultsBaseline characteristics did not differ significantly between groups. Placebo-subtracted peak glucose was significantly lowered in PGR and significantly increased in PGNR (−43.8 and 17.9 mg/dL; both p < 0.05). Luseogliflozin significantly lowered “lowest glucose” (defined as the lowest level measured throughout a 24-h period) similarly in PGR and PGNR (−19.2 and −24.0 mg/dL; both p < 0.05), significantly reduced the mean amplitude of glucose excursions in PGR (−15.50 mg/dL; p < 0.05), and increased the area under the curve for plasma glucagon over 24 h in PGNR (median difference vs. placebo: 240 pg/mL h; p < 0.05). Luseogliflozin increased urinary glucose excretion (UGE) and decreased serum insulin by similar magnitudes in both groups.ConclusionsLuseogliflozin diminished glucose fluctuations in most patients by lowering peak glucose to a greater extent than lowest glucose. Luseogliflozin may also lower lowest glucose in patients whose peak glucose was not ameliorated despite increasing UGE. The glucagon increase in PGNR might explain its hypoglycemic effect on postprandial glucose.FundingTaisho Pharmaceutical Co., Ltd, Tokyo, Japan.Trial RegistrationJapicCTI-142548.
28 schema:genre article
29 schema:isAccessibleForFree true
30 schema:isPartOf N0b789d4596ed447daecaadcd8d8f3e7f
31 Nef743f649d63432fbda05d7ae89f6098
32 sg:journal.1096634
33 schema:keywords Analyzing Responses
34 Co.
35 Controlled Study
36 Japan
37 Japanese type 2 diabetic patients
38 Ltd
39 PgR
40 ResultsBaseline characteristics
41 Tokyo
42 administration
43 amplitude
44 area
45 baseline characteristics
46 characteristics
47 continuous glucose monitoring
48 cotransporter 2 inhibitors
49 crossover study
50 curves
51 data
52 diabetic patients
53 differential effects
54 downward shift
55 effect
56 effect of luseogliflozin
57 excretion
58 excursion
59 extent
60 factors
61 fluctuations
62 further review
63 glucagon
64 glucagon increase
65 glucose
66 glucose excretion
67 glucose excursions
68 glucose fluctuations
69 glucose levels
70 glucose monitoring
71 glucose response
72 glycemic variability
73 greater extent
74 group
75 hyperglycemia
76 hypoglycemic effect
77 increase
78 individual patients
79 inhibitors
80 insulin
81 levels
82 low glucose
83 luseogliflozin
84 luseogliflozin administration
85 magnitude
86 mean amplitude
87 monitoring
88 most patients
89 parallel downward shift
90 patients
91 peak glucose
92 pharmacodynamic variability
93 plasma glucagon
94 postprandial glucose
95 postprandial glucose levels
96 postprandial glucose response
97 postprandial hyperglycemia
98 preprandial glucose
99 previous studies
100 responders
101 response
102 review
103 serum insulin
104 shift
105 similar magnitude
106 sodium-glucose cotransporter 2 inhibitors
107 study
108 subanalyses
109 substantial effect
110 type 2 diabetic patients
111 urinary glucose excretion
112 variability
113 variation
114 schema:name Substantial Effects of Luseogliflozin Revealed by Analyzing Responses to Postprandial Hyperglycemia: Post Hoc Subanalyses of a Randomized Controlled Study
115 schema:pagination 1215-1230
116 schema:productId N5c2da688b26f4d499a7af063d980164b
117 N6b2ff56917dd40fea000dc18107a28e8
118 N830c0921509942549e007a6e7772ed2b
119 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003457836
120 https://doi.org/10.1007/s12325-016-0350-5
121 schema:sdDatePublished 2022-10-01T06:41
122 schema:sdLicense https://scigraph.springernature.com/explorer/license/
123 schema:sdPublisher N191eb0fcd30343f48d712e312c1d9f41
124 schema:url https://doi.org/10.1007/s12325-016-0350-5
125 sgo:license sg:explorer/license/
126 sgo:sdDataset articles
127 rdf:type schema:ScholarlyArticle
128 N0ae43fee7ceb4a48a05e5aa4c53d66c7 rdf:first sg:person.01034253641.66
129 rdf:rest N371d8013a2ce40a7ad9c98c5e953a2c9
130 N0b789d4596ed447daecaadcd8d8f3e7f schema:volumeNumber 33
131 rdf:type schema:PublicationVolume
132 N191eb0fcd30343f48d712e312c1d9f41 schema:name Springer Nature - SN SciGraph project
133 rdf:type schema:Organization
134 N22d95ff84ede41f6b5e5520a67da6650 rdf:first sg:person.01044115456.01
135 rdf:rest N0ae43fee7ceb4a48a05e5aa4c53d66c7
136 N3453fb57ec774d3aadce6e3f91aca816 rdf:first sg:person.0745514477.90
137 rdf:rest rdf:nil
138 N371d8013a2ce40a7ad9c98c5e953a2c9 rdf:first sg:person.01362135451.72
139 rdf:rest N737ca6148b3741fc9171b11d01ab8c56
140 N3f73886f43f14703ad24fd862701e078 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Double-Blind Method
142 rdf:type schema:DefinedTerm
143 N3fc498d775df4e739ccb5a0ed115afc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Sorbitol
145 rdf:type schema:DefinedTerm
146 N49411d0a4ecd4270989ef2cb0eae1739 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Japan
148 rdf:type schema:DefinedTerm
149 N50cab4b59fe242deb040c996a2b5a6c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Blood Glucose
151 rdf:type schema:DefinedTerm
152 N5c2da688b26f4d499a7af063d980164b schema:name dimensions_id
153 schema:value pub.1003457836
154 rdf:type schema:PropertyValue
155 N665f589670b0489c9e2d395844f54299 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Male
157 rdf:type schema:DefinedTerm
158 N675e3d09d908497ebf1cf63dc797fd41 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Hypoglycemic Agents
160 rdf:type schema:DefinedTerm
161 N6b2ff56917dd40fea000dc18107a28e8 schema:name pubmed_id
162 schema:value 27255763
163 rdf:type schema:PropertyValue
164 N700f8149353a4c288b6bf4b124b3c700 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Middle Aged
166 rdf:type schema:DefinedTerm
167 N711fdf809ca54d14b7541dd5d59700cf rdf:first sg:person.01133661156.29
168 rdf:rest N3453fb57ec774d3aadce6e3f91aca816
169 N71b3113eae1e49b9b6e0a41c354b2eb2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Aged
171 rdf:type schema:DefinedTerm
172 N737ca6148b3741fc9171b11d01ab8c56 rdf:first sg:person.01314022251.64
173 rdf:rest N711fdf809ca54d14b7541dd5d59700cf
174 N7679a15c114948f6a4b3d554fe302440 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Hyperglycemia
176 rdf:type schema:DefinedTerm
177 N830c0921509942549e007a6e7772ed2b schema:name doi
178 schema:value 10.1007/s12325-016-0350-5
179 rdf:type schema:PropertyValue
180 Nb2143e78fe814540a5f29e735b65a988 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Female
182 rdf:type schema:DefinedTerm
183 Nb835c7e2b1374aeeb1387b6bd6a1bfc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
184 schema:name Humans
185 rdf:type schema:DefinedTerm
186 Ne0466cc0229849099ec9b11e1aa49d68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Postprandial Period
188 rdf:type schema:DefinedTerm
189 Ne85683e735014b0b91d823e181334cc3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
190 schema:name Diabetes Mellitus, Type 2
191 rdf:type schema:DefinedTerm
192 Neec0b93a95a245b189be66ce2f058fee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Cross-Over Studies
194 rdf:type schema:DefinedTerm
195 Nef743f649d63432fbda05d7ae89f6098 schema:issueNumber 7
196 rdf:type schema:PublicationIssue
197 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
198 schema:name Medical and Health Sciences
199 rdf:type schema:DefinedTerm
200 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
201 schema:name Clinical Sciences
202 rdf:type schema:DefinedTerm
203 sg:journal.1096634 schema:issn 0741-238X
204 1865-8652
205 schema:name Advances in Therapy
206 schema:publisher Springer Nature
207 rdf:type schema:Periodical
208 sg:person.01034253641.66 schema:affiliation grid-institutes:grid.419836.1
209 schema:familyName Omiya
210 schema:givenName Hirohisa
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01034253641.66
212 rdf:type schema:Person
213 sg:person.01044115456.01 schema:affiliation grid-institutes:grid.419836.1
214 schema:familyName Samukawa
215 schema:givenName Yoshishige
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01044115456.01
217 rdf:type schema:Person
218 sg:person.01133661156.29 schema:affiliation grid-institutes:grid.419836.1
219 schema:familyName Sakai
220 schema:givenName Soichi
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01133661156.29
222 rdf:type schema:Person
223 sg:person.01314022251.64 schema:affiliation grid-institutes:grid.419836.1
224 schema:familyName Nozaki
225 schema:givenName Kazunari
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314022251.64
227 rdf:type schema:Person
228 sg:person.01362135451.72 schema:affiliation grid-institutes:grid.419836.1
229 schema:familyName Watase
230 schema:givenName Hirotaka
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01362135451.72
232 rdf:type schema:Person
233 sg:person.0745514477.90 schema:affiliation grid-institutes:grid.411898.d
234 schema:familyName Nishimura
235 schema:givenName Rimei
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745514477.90
237 rdf:type schema:Person
238 sg:pub.10.1007/s12272-014-0419-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048225579
239 https://doi.org/10.1007/s12272-014-0419-0
240 rdf:type schema:CreativeWork
241 sg:pub.10.1007/s12325-015-0200-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1027959488
242 https://doi.org/10.1007/s12325-015-0200-x
243 rdf:type schema:CreativeWork
244 sg:pub.10.1007/s13300-013-0042-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1005579084
245 https://doi.org/10.1007/s13300-013-0042-y
246 rdf:type schema:CreativeWork
247 sg:pub.10.1007/s40265-014-0230-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007759159
248 https://doi.org/10.1007/s40265-014-0230-8
249 rdf:type schema:CreativeWork
250 sg:pub.10.1038/nm.3828 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033956920
251 https://doi.org/10.1038/nm.3828
252 rdf:type schema:CreativeWork
253 sg:pub.10.1038/nrendo.2011.243 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038216268
254 https://doi.org/10.1038/nrendo.2011.243
255 rdf:type schema:CreativeWork
256 sg:pub.10.1186/s12933-014-0169-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040395366
257 https://doi.org/10.1186/s12933-014-0169-9
258 rdf:type schema:CreativeWork
259 grid-institutes:grid.411898.d schema:alternateName Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-19-18 Nishi-shimbashi, Minato-ku, 105-0003, Tokyo, Japan
260 schema:name Division of Diabetes, Metabolism and Endocrinology, Department of Internal Medicine, Jikei University School of Medicine, 3-19-18 Nishi-shimbashi, Minato-ku, 105-0003, Tokyo, Japan
261 rdf:type schema:Organization
262 grid-institutes:grid.419836.1 schema:alternateName Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan
263 schema:name Taisho Pharmaceutical Co., Ltd., 3-24-1 Takada, Toshima-ku, 170-8633, Tokyo, Japan
264 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...